InsidersTradesSigma
Edgewise Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)
SEC:edgewise-therapeutics-inc-58ef88US·SEC (Form 4)Mcap 2.6Bn€Healthcare & Pharma
Explore the full directors' dealings record of Edgewise Therapeutics, Inc., a listed equity based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Edgewise Therapeutics, Inc. has recorded 35 reports. Market capitalisation: €2.6bn. The latest transaction was filed on 21 June 2022 — Levée d'options. Among the most active insiders: Russell Alan J. Every trade is accessible without an account.
35
Insider Decl.
0
Thresholds
€2m
2 ops.
Buy Volume
€2m
21 ops.
Sell Volume
Financial data
33.09 €
Analyst consensus
12 analystsBuy
20.00 €Target 43.67 €(+32%)52.00 €
Income statement
Net income−167.8 M€0.0% margin
Valuation
PER (forward)-14.2x
P/Book7.2x
Beta0.25
Balance sheet & cash
Market cap2.63 Bn€
Total debt4.0 M€
Free Cash Flow−144.1 M€
Debt / Equity1%
Profitability & ownership
ROE-38.1%
ROA-25.6%
% insiders0.5%
% institutions113.6%
Last declaration on 21 June 2022
Declarations35 total
Executives◇Options20SEC
€26,94014,722 shares@ €1.82990.0010% mcap17.3% of flow
Common Stock
SEC:0001562180-22-005251:0·
Executives◇Options18SEC
€2,7904,093 shares@ €0.68170.0001% mcap1.8% of flow
Common Stock
SEC:0001562180-22-005126:0·
Executives◇Options19SEC
€8,32412,566 shares@ €0.66250.0003% mcap5.3% of flow
Common Stock
SEC:0001562180-22-005053:0·
Executives◇Options20SEC
€27,34015,230 shares@ €1.79520.0010% mcap17.6% of flow
Common Stock
SEC:0001562180-22-004887:0·
Executives◇Options34SEC
€5,9829,000 shares@ €0.66470.0002% mcap100.0% of flow
Common Stock
SEC:0001562180-22-004407:0·
Executives▲Purchase◆Signal · 46SEC
€950,067138,000 shares@ €6.88450.036% mcap100.0% of flow
Common Stock
SEC:0000947871-22-000629:0·
Ideal exit: 12 Feb 2023 (T+270)
Executives▲Purchase◆Signal · 46SEC
€950,067138,000 shares@ €6.88450.036% mcap100.0% of flow
Common Stock
SEC:0000947871-22-000628:0·
Ideal exit: 12 Feb 2023 (T+270)
Executives▼Sale23SEC
€76,77610,800 shares@ €7.10890.0029% mcap49.3% of flow
Common Stock
SEC:0001562180-22-004201:0·
Executives◇Options21SEC
€3,3895,400 shares@ €0.62760.0001% mcap50.0% of flow
Common Stock
SEC:0001562180-22-000645·
Executives◇Options18SEC
€3,3895,400 shares@ €0.62760.0001% mcap2.2% of flow
Common Stock
SEC:0001562180-22-000645:0·
Executives◇Options21SEC
€3,3845,400 shares@ €0.62670.0001% mcap50.0% of flow
Common Stock
SEC:0001562180-21-007920·
Executives◇Options18SEC
€3,3845,400 shares@ €0.62670.0001% mcap2.2% of flow
Common Stock
SEC:0001562180-21-007920:0·
Executives◇Options16SEC
€23,523147,585 shares@ €0.15940.0009% mcap2.0% of flow
Common Stock
SEC:0001562180-21-007369·
Executives◇Options18SEC
€23,523147,585 shares@ €0.15940.0009% mcap1.0% of flow
Common Stock
SEC:0001562180-21-007369:0·
Executives▼Sale16SEC
€7,351441 shares@ €16.66790.0003% mcap0.6% of flow
Common Stock
SEC:0001562180-21-007134·
Executives▼Sale18SEC
€7,351441 shares@ €16.66790.0003% mcap0.3% of flow
Common Stock
SEC:0001562180-21-007134:0·
Executives▼Sale20SEC
€290,10416,864 shares@ €17.20260.011% mcap25.1% of flow
Common Stock
SEC:0001562180-21-007025·
Executives▼Sale20SEC
€290,10416,864 shares@ €17.20260.011% mcap12.5% of flow
Common Stock
SEC:0001562180-21-007025:0·
Executives▼Sale17SEC
€125,7707,392 shares@ €17.01440.0048% mcap10.9% of flow
Common Stock
SEC:0001562180-21-006901·
Executives▼Sale19SEC
€125,7707,392 shares@ €17.01440.0048% mcap5.4% of flow
Common Stock
SEC:0001562180-21-006901:0·
Executives▼Sale16SEC
€7,315469 shares@ €15.59670.0003% mcap0.6% of flow
Common Stock
SEC:0001562180-21-006811·
Executives▼Sale18SEC
€7,315469 shares@ €15.59670.0003% mcap0.3% of flow
Common Stock
SEC:0001562180-21-006811:0·
Executives▼Sale17SEC
€90,1675,749 shares@ €15.68390.0034% mcap7.8% of flow
Common Stock
SEC:0001562180-21-006498·
Executives▼Sale18SEC
€90,1675,749 shares@ €15.68390.0034% mcap3.9% of flow
Common Stock
SEC:0001562180-21-006498:0·
25 of 35 declarations
About Edgewise Therapeutics, Inc.
Recent highlights include Edgewise’s early-May 2026 first-quarter financial update and clinical progress report in muscular dystrophy and cardiovascular programs. The company also outlined 2026 corporate priorities and announced participation in a RBC Capital Markets healthcare conference in May 2026. In the context of SEC Form 4 insider filings, investors should interpret insider transactions carefully, as they often reflect equity compensation or prearranged 10b5-1 plans rather than a standalone fundamental signal. Overall, Edgewise remains a specialty biotech name with meaningful scientific optionality, but also a high-risk profile typical of clinical-stage companies.
